Trial Profile
Redosing With CP-870,893 in Patients With Clinical Benefit After a Single Infusion of CP-870,893 From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs CP 870893 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 11 Jul 2014 New trial record